Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960285 | 0.94 | ALDH1A1 (0.40) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL2957660 | 0.93 | CPT1A (0.41) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL2960057 | 0.87 | MAPT (0.44) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL2957792 | 0.83 | ACHE (0.43) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL13198971 | 0.82 | MAPT (0.42) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL13198993 | 0.82 | MAPT (0.45) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL13199002 | 0.81 | MAPT (0.45) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL2948289 | 0.79 | TLR9 (0.42) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL2961877 | 0.79 | KMT2A (0.45) | NPC1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL2953799 | 0.77 | KMT2A (0.39) | NPC1SMN1; SMN2ALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | claimed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | claimed |
| US-7767681-B2 | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-03 | — | — | US | disclosed |
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1603860-A4 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
| EP-1771425-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006016039-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | WO | disclosed |
| EP-1603860-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004072254-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | UGT2B7, PKD2, CYP2C19 | NPC1 155/4885SMN1; SMN2 868/4885ALDH1A1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.